Dermalux
ActiveSummary
Dermalux has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5,000 and a net result of €100,510. Equity remains stable across the filed financial years (±0% per year). Its solvency ranks better than 7% of 20,659 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
- Equity
- €5,000
- Profit
- €100,510
Why 91raises riskEquity €5,000 (2.6% of total assets)lowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 1.00, cash €85,791Size: total assets €191,033Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 8% on solvency, 20% on liquidity, 80% on profitability and 5% on growth.
The bankruptcy probability was computed on 30-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 3 accounts on average 29 days before the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
- Annual accounts filedfinancial year 2025 · micro…
- Highest result from 2023 to 2025net €100,510 ▲1.3%
- Annual accounts filedfinancial year 2024 · unclassified…
Financials · financial year 2025, micro format
2023 to 2025, 3 financial years
The operating result has risen two years in a row; 2025 is 1% above 2024 and is the highest result in the available series.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Peer companies
Historical observationOf the 2,157 companies that looked in July 2024 the way this one looks now, 3.0% went bankrupt within 24 months and 94.1% are still going.
- Micro
- 2 to 5 years old
- solvency under 10%
- a profit of 5% of the balance sheet or more
A further 0.1% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: < 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 2,157 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | - | €129 | - |
| Other operating charges640/8 | €198 | - | - | - |
| Gross operating margin9900 | €93,126 | €126,108 | €127,589 | ▲ 1.2% |
| Operating profit (loss)9901 | €92,928 | €126,108 | €127,460 | ▲ 1.1% |
| Financial charges65/66B | €75 | €74 | €75 | ▲ 2.0% |
| Recurring financial charges65 | €75 | €74 | €75 | ▲ 2.0% |
| Profit (loss) for the period before taxes9903 | €92,853 | €126,034 | €127,385 | ▲ 1.1% |
| Income taxes67/77 | €18,571 | €26,797 | €26,875 | ▲ 0.3% |
| Profit (loss) for the period9904 | €74,282 | €99,237 | €100,510 | ▲ 1.3% |
| Profit (loss) for the period to be appropriated9905 | €74,282 | €99,237 | €100,510 | ▲ 1.3% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €109,005 | €175,760 | €191,033 | ▲ 8.7% |
| Fixed assets21/28 | - | - | €5,868 | - |
| Tangible fixed assets22/27 | - | - | €5,868 | - |
| Furniture and vehicles24 | - | - | €5,868 | - |
| Current assets29/58 | €109,005 | €175,760 | €185,165 | ▲ 5.4% |
| Amounts receivable within one year40/41 | €71,731 | €102,714 | €98,998 | ▼ 3.6% |
| Trade receivables40 | €9,245 | €102,714 | €98,998 | ▼ 3.6% |
| Other amounts receivable41 | €62,486 | - | - | - |
| Cash at bank and in hand54/58 | €36,438 | €72,671 | €85,791 | ▲ 18.1% |
| Deferred charges and accrued income490/1 | €836 | €376 | €376 | = |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €109,005 | €175,760 | €191,033 | ▲ 8.7% |
| Equity10/15 | €5,000 | €54,237 | €5,000 | ▼ 90.8% |
| Contributions10/11 | €5,000 | €5,000 | €5,000 | = |
| Profit (loss) carried forward14 | - | €49,237 | - | - |
| Amounts payable17/49 | €104,005 | €121,524 | €186,033 | ▲ 53.1% |
| Amounts payable within one year42/48 | €104,005 | €121,524 | €186,033 | ▲ 53.1% |
| Trade debts44 | €3,533 | €34,082 | €33,568 | ▼ 1.5% |
| Suppliers440/4 | €3,533 | €34,082 | €33,568 | ▼ 1.5% |
| Advances received on contracts in progress46 | - | €5,000 | - | - |
| Taxes, remuneration and social security45 | €31,294 | €38,525 | €65,012 | ▲ 68.8% |
| Taxes450/3 | €31,294 | €38,525 | €65,012 | ▲ 68.8% |
| Other amounts payable47/48 | €69,177 | €43,917 | €87,453 | ▲ 99.1% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | €74,282 | €99,237 | €100,510 | ▲ 1.3% |
| + Depreciation and write-downs630 | - | - | €129 | - |
| Operating cash flow (approximation) | €74,282 | €99,237 | €100,639 | ▲ 1.4% |
| Change in cash | - | €36,232 | €13,120 | ▼ 63.8% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (3)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 06-07-2026 | 2026-00254707 |
| 31-12-2024 | unclassified schema | 03-07-2025 | 2025-00223134 |
| 31-12-2023 | unclassified schema | 27-06-2024 | 2024-00169306 |
Similar companies · same sector, comparable size
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Mandate history
- Board
| Name | Functions and periods |
|---|---|
| Meike FÖRSTER |
|
Owners and capital
Capital and shareholders
- Meike FÖRSTER 100 shares (100%) · €5,000 · Barzahlung
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 27-01-2023 Incorporation · €5,000 · 100 shares
Group and network
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
History
Dermalux was incorporated on 25 January 2023 as a private limited company by one natural person, with a starting capital of €5,000.12 The registered office was moved to Kelmis in 2023.3 Since 2023, Meike FÖRSTER has served as nicht satzungsgemäßer verwalter of the company.2 Total assets rose from €109,005 in 2023 to €191,033 in 2025.4
Acts, filings and financial milestones
19-12
Gazette deed
GesellschaftssitzRegistered-office move · Director in office3 facts ▸
- Board meeting, 01-12-2023
- Registered-office move, Kirchplatz 27-29 in 4720 Kelmis
- Director in office, Meike Förster (verwalterin)
27-01
Gazette deed
IncorporationAppointment: Meike FÖRSTER (nicht satzungsgemäßer verwalter) · Founder · Founding capital8 facts ▸
- Incorporation, 23-01-2023
- Founder, Meike FÖRSTER
- Founding capital, €5,000
- Other provision, “Finanzplan, Haftung bei Konkurs innerhalb 3 Jahren bei offensichtlich unzureichendem Kapital” (deed in German)
- Other provision, “Eigenkapitalausreichung, als verfügbar verbucht” (deed in German)
- Registered office clause, “Loten 3,4700 Eupen” (deed in German)
- Board rule, 1, “Generalversammlung” (deed in German)
- Director appointment, Meike FÖRSTER (nicht satzungsgemäßer verwalter)
Register details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 31 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
1 establishment unit
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 63040A0034/03_000 | Wallonia | 2,701 m² | - | - |
How the parcels are linked
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “Die Gesellschaft hat zum Gegenstand die Ausübung der Medizin, und insbesondere der Dermatologie, durch den oder die Aktionäre, die sie…” (deed in German)
5 activities (deed in German)
- Die Gesellschaft hat zum Gegenstand die Ausübung der Medizin, und insbesondere der Dermatologie, durch den oder die Aktionäre, die sie bilden, welche ausschließlich in der Liste der Ärztekammer eingetragene Ärzte sein müssen.
- Die Medizin wird im Namen und für Rechnung der Gesellschaft ausgeübt.
- Falls es mehrere Aktionäre gibt, stellen diese die Gesamtheit ihrer medizinischen Tätigkeiten innerhalb der Gesellschaft zur Verfügung.
- Die Honorare werden durch und für die Gesellschaft eingezogen.
- Im Zusammenhang mit diesem Gegenstand kann die Gesellschaft alle zivilen, mobiliarischen oder immobiliarischen Tätigkeiten ausüben, insbesondere auch den Vertrieb von Nahrungsergänzungsmitteln und die allgemeine Beratung im gewerblichen Umfeld.
- Name clauseThe name the company operates under according to its articles.
- Dermalux
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- One provision in the deed
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Verwaltungsorgan, 1” (deed in German)“Durch Generalversammlung für Dauer der Gesellschaft” (deed in German)“Mit Bedingungen für Statutenänderungen an Mehrheit und Anwesenheit, durch Generalversammlung mit einfacher Mehrheit der vertretenen Stimmen” (deed in German)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Namensaktien, Namensaktienbuch” (deed in German)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Einstimmigkeit der teilhabenden Ärzte bei mehreren Aktionären, unteilbar,nur ein Eigentümer pro Titel” (deed in German)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- “Durchführung und Einberufung Jährlich wird am vierten Montag des Monats Mai um 19 Uhr eine ordentliche Generalversammlung am Sitz…” (deed in German)
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- One provision in the deed
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Bereinigung Schulden,Kosten,Liquidationsaufwendungen oder Hinterlegung,Gleichstellung nicht vollständig freigegebener Aktien durch…” (deed in German)